Eli Lilly
| Type | Public |
| HQ | Indianapolis, US |
| Founded | 1876 |
| Size (employees) | 38,160 (est)-6% |
| Website | lilly.com |
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Eli Lilly
David A. Ricks
Chairman and Chief Executive Officer
Melissa Stapleton Barnes
Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer
Enrique A. Conterno
Senior Vice President and President, Lilly Diabetes and Lilly USA
Stephen F. Fry
Senior Vice President, Human Resources and Diversity
Michael J. Harrington
Senior Vice President and General Counsel
Johna L. Norton
Senior Vice President, Global Quality
Report incorrect company information
Eli Lilly Office Locations
Eli Lilly has offices in Indianapolis, Melrose Park, Toronto, Wien and in 141 other locations
Indianapolis, (HQ)
Lilly Corporate Center
Melrose Park,
112 Wharf Rd
Wien,
8-10 Kölblgasse
Toronto,
3650 Danforth Ave
Chuo Ward,
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe
Windlesham,
Erl Wood Manor Sunninghill Road
Report incorrect company information
Eli Lilly Financials and Metrics
Eli Lilly Revenue
Eli Lilly's revenue was reported to be $21.22 b in FY, 2016 which is a 6.3% increase from the previous period.
| USD | |
|---|---|
Market capitalization (12-Dec-2018) | 121.1b |
Closing stock price (12-Dec-2018) | 114.3 |
Cash (30-Sep-2018) | 9.0b |
Eli Lilly's current market capitalization is $121.1 b.
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|
Cash | 3.8b | 3.9b | 3.7b | 4.6b | |
Accounts Receivable | 588.4m | 566.7m | 558.6m | 736.9m | |
Inventories | 2.9b | 2.7b | 3.4b | 3.6b | |
Current Assets | 13.1b | 12.2b | 12.6b | 15.1b |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 4.7b | 2.4b | 2.4b | 2.7b |
Cash From Operating Activities | 5.7b | 4.4b | 2.8b | 4.9b |
Purchases of PP&E | (1.0b) | (1.2b) | (1.1b) | (1.0b) |
Cash From Investing Activities | (2.1b) | (3.9b) | 26.8m | (3.1b) |
Eli Lilly Operating Metrics
| FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | |
|---|---|---|---|---|
Phase III Trials Products | 8 | 7 | 17 | 19 |
Projects in R&D Pipeline | 57 | 57 | 65 | 66 |
Eli Lilly Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| AurKa Pharma | May 15, 2018 | $575 m |
| ARMO BioSciences Inc | May 11, 2018 | $1.60 b |
| CoLucid Pharmaceuticals | January 18, 2017 | $960 m |
| Novartis Animal Health | April 22, 2014 | $5.40 b |
| Avid Radiopharmaceuticals | November 08, 2010 | $800 m |
| Alnara Pharmaceuticals | July 02, 2010 | $280 m |
| Imclone Systems | October 06, 2008 | $6.50 b |
Report incorrect company information
Eli Lilly Online and Social Media Presence
Report incorrect company information
Eli Lilly News and Updates
December 13, 2018
Diabetic Therapeutic Drugs Global Market 2018: Key Players – Pfizer, Novartis, AstraZeneca, Eli Lilly, Merck
Wiseguyreports.Com adds “Diabetic Therapeutic Drugs Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday
December 12, 2018
Diabetes Management Global Market 2018-2023: Abbott, Bayer, Eli Lilly, Sanofi, Dexcom, Medtronic
Wiseguyreports.Com Publish New Market Research Report On -“Diabetes Management Market - Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2018 - 2023” Posted via Industry Today. Follow us on Twitter @IndustryToday
December 07, 2018
Breast cancer therapeutic Market Size, Market Share And Industry Growth Analysis, market trends, Forecast 2025 by AstraZeneca, Eisai,Eli Lilly ,Company,F. Hoffmann-La Roche
Global Breast cancer therapeutic Market is expected to grow at a Compound Annual Growth Rate (CAGR) of +11.63%. The base year considered for the study is 2018 and the forecast period considered is 2018 To 2025 Posted via Industry Today. Follow us on Twitter @IndustryToday
November 27, 2018
Injection Pen Market Outlook with Expected 9.5% CAGR 2018-2025 | Global key Players Owen Mumford Ltd, Eli Lilly And Company, GlaxoSmithKline plc, Mylan N.V., Astra Zeneca, Novo Nordisk
Qurate Business Intelligence Adds “Injection Pen Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database Posted via Industry Today. Follow us on Twitter @IndustryToday
November 26, 2018
Global Diabetes Drug Market Report 2018-2024 Featuring Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson & Boehringer Ingelheim
DUBLIN, Nov. 26, 2018 /PRNewswire/ -- The "Diabetes Drug Market, Oral, Injection, Regions, and Companies" report has been added to ResearchAndMarkets.com's offering. Global diabetes drug market is expected to surpass US$ 76 Billion by the end of the year 2024 Rising global diabetes...
November 22, 2018
Human Recombinant Insulin Market Increased International Trends and Opening New Opportunities till 2026 By Global Key Players Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A.
#Summary: Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twitter…
Report incorrect company information
Eli Lilly Company Life and Culture
Report incorrect company information
Eli Lilly Frequently Asked Questions
When was Eli Lilly founded?
Eli Lilly was founded in 1876.
Who are Eli Lilly key executives?
Eli Lilly's key executives are David A. Ricks, Melissa Stapleton Barnes and Enrique A. Conterno.
How many employees does Eli Lilly have?
Eli Lilly has 38,160 employees.
What is Eli Lilly revenue?
Latest Eli Lilly annual revenue is $21.2 b.
What is Eli Lilly revenue per employee?
Latest Eli Lilly revenue per employee is $556.1 k.
Who are Eli Lilly competitors?
Competitors of Eli Lilly include Pfizer, GlaxoSmithKline and Merck.
Where is Eli Lilly headquarters?
Eli Lilly headquarters is located at Lilly Corporate Center , Indianapolis.
Where are Eli Lilly offices?
Eli Lilly has offices in Indianapolis, Melrose Park, Toronto, Wien and in 141 other locations.
How many offices does Eli Lilly have?
Eli Lilly has 196 offices.